A case of malignant haemangioendothelioma treated with recombinant interleukin-2.
A case of malignant haemangioendothelioma of the scalp in an 82-year-old female treated with intralesional, intra-arterial and intravenous recombinant interleukin-2 (rIL-2) is reported. The scalp lesions disappeared after injection of 35,350,000 Japan reference units of rIL-2 and excision of the residual tumour. Immunohistochemical characterization of the cells infiltrating the lesion after rIL-2 administration revealed 30-40% CD4+ and CD8+ T lymphocytes, 20-30% macrophages and 5-10% natural killer cells. These findings are similar to those in other human cancers. Almost all of the cells in the intersticies of the lesion after rIL-2 injection expressed leucocyte function-associated antigen-1, and some of the tumour cells and the infiltrating cells around them expressed intercellular adhesion molecule-1. HLA-DR-positive cells markedly increased in number after rIL-2 administration. This report suggests that rIL-2 administration is the most effective therapy for malignant haemangioendothelioma.
Ansai
S
S
Department of Dermatology, Yamagata University, Faculty of Medicine, Japan.
Goto
K
K
Aoki
T
T
Hozumi
Y
Y
Aso
K
K
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006390:Hemangioendothelioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D012535:Scalp / Q000473:pathology*; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D007376:Interleukin-2